These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25564200)

  • 1. The impact of pharmaceutical innovation on premature mortality, cancer mortality, and hospitalization in Slovenia, 1997-2010.
    Lichtenberg FR
    Appl Health Econ Health Policy; 2015 Apr; 13(2):207-22. PubMed ID: 25564200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of pharmaceutical innovation on premature cancer mortality in Switzerland, 1995-2012.
    Lichtenberg FR
    Eur J Health Econ; 2016 Sep; 17(7):833-54. PubMed ID: 26342826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000-2011.
    Lichtenberg FR
    Int J Health Econ Manag; 2015 Sep; 15(3):339-359. PubMed ID: 27878681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999-2010.
    Lichtenberg FR; Tatar M; Çalışkan Z
    Health Policy; 2014 Sep; 117(3):361-73. PubMed ID: 24996837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of pharmaceutical innovation on the longevity and hospitalization of New Zealand cancer patients, 1998-2017.
    Lichtenberg FR
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):476-477. PubMed ID: 33412958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Pharmaceutical Innovation on Cancer Mortality in Belgium, 2004-2012.
    Lichtenberg FR
    Forum Health Econ Policy; 2016 Sep; 20(1):. PubMed ID: 31419903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of pharmaceutical innovation on the burden of disease in Canada, 2000-2016.
    Lichtenberg FR
    SSM Popul Health; 2019 Aug; 8():100457. PubMed ID: 31440578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Years of potential life lost and valued years of potential life lost in assessing premature mortality in Slovenia.
    Semerl JS; Sesok J
    Croat Med J; 2002 Aug; 43(4):439-45. PubMed ID: 12187522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: A Two-Way Fixed-Effects Analysis.
    Lichtenberg FR
    Forum Health Econ Policy; 2019 Apr; 21(2):. PubMed ID: 31017868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000-2009.
    Lichtenberg FR
    Econ Hum Biol; 2014 Mar; 13():107-27. PubMed ID: 23664114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of hospital records in four African countries, 1975-1990, with emphasis on infectious diseases.
    Petit PL; van Ginneken JK
    J Trop Med Hyg; 1995 Aug; 98(4):217-27. PubMed ID: 7636917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999-2007.
    Lichtenberg FR
    Eur J Health Econ; 2013 Feb; 14(1):41-56. PubMed ID: 21953319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How many life-years have new drugs saved? A three-way fixed-effects analysis of 66 diseases in 27 countries, 2000-2013.
    Lichtenberg FR
    Int Health; 2019 Sep; 11(5):403-416. PubMed ID: 30912800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The adoption of pharmaceutical innovation and its impact on the treatment costs for Alzheimer's disease in Taiwan.
    Lo TF; Hsieh CR
    J Ment Health Policy Econ; 2014 Sep; 17(3):107-17. PubMed ID: 25543114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Relationship Between Pharmaceutical Innovation and Cancer Mortality in Spain, From 1999 to 2016.
    Lichtenberg FR
    Value Health; 2023 Dec; 26(12):1711-1720. PubMed ID: 37741448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Premature mortality in Slovenia in relation to selected biological, socioeconomic, and geographical determinants.
    Artnik B; Vidmar G; Javornik J; Laaser U
    Croat Med J; 2006 Feb; 47(1):103-13. PubMed ID: 16489703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of pharmaceutical innovation on longevity: Evidence from the U.S. and 26 high-income countries.
    Lichtenberg FR
    Econ Hum Biol; 2022 Aug; 46():101124. PubMed ID: 35344806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical innovation and the longevity of Australians: a first look.
    Lichtenberg FR; Duflos G
    Adv Health Econ Health Serv Res; 2008; 19():95-117. PubMed ID: 19548515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Deaths in a Tunisian psychiatric hospital: an eleven-year retrospective study].
    Zgueb Y; Jomli R; Ouertani A; Hechmi S; Ouanes S; Nacef F; Banaser A
    Encephale; 2014 Oct; 40(5):416-22. PubMed ID: 25132014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
    Hristova L; Hakama M
    Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.